ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000901

Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus

Identifieur interne : 000901 ( PascalFrancis/Corpus ); précédent : 000900; suivant : 000902

Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus

Auteurs : Katerina Venderov ; Timothy M. Brown ; Jonathan M. Brotchie

Source :

Experimental neurology : (Print) [ 0014-4886 ] ; 2005.

RBID : Pascal:05-0317987

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Cannabinoïde, GABA, Captation, Animal, Rat, Récepteur cannabinoïde CB1, Neurone gabaergique, Glycérol, Noyau gris central.

English descriptors

KwdEn :
- Animal, Basal ganglion, CB1 cannabinoid receptor, Cannabinoid, GABA, Gabaergic neuron, Glycerol, Parkinson disease, Rat, Uptake.

Abstract

In the globus pallidus, cannabinoid CB₁ receptors are localized pre-synaptically on GABAergic neurons. We assessed the influence of the endocannabinoids, anandamide, 2-arachidonoyl-glycerol (2-AG) and noladin ether, on the uptake of [³H]-GABA in pallidal slices from rat. Both 2-AG and noladin ether increased [³H]-GABA uptake (by 40.8 ± 8.0% and 38.4 ± 12.5%). The effect of 2-AG was blocked by the cannabinoid CB₁ receptor antagonist AM 251. In contrast, neither anandamide nor the agonist WIN 55,212-2 had an effect on [³H]-GABA uptake. Different roles might be played by different endocannabinoids, both physiologically and in basal ganglia disorders, such as Parkinson's disease.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0014-4886`
A02	`01`			`@0 EXNEAC`
A03		`1`		`@0 Exp. neurol. : (Print)`
A05				`@2 194`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Differential effects of endocannabinoids on [³H]-GABA uptake in the rat globus pallidus`
A11	`01`	`1`		`@1 VENDEROV (Katerina)`
A11	`02`	`1`		`@1 BROWN (Timothy M.)`
A11	`03`	`1`		`@1 BROTCHIE (Jonathan M.)`
A14	`01`			`@1 Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, MC 11-419 @2 Toronto, Ontario, M5T 258 @3 CAN @Z 1 aut. @Z 3 aut.`
A14	`02`			`@1 School of Biological Sciences, University of Manchester @2 Manchester @3 GBR @Z 2 aut.`
A20				`@1 284-287`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 9181 @5 354000124651760240`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 05-0317987`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Experimental neurology : (Print)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 In the globus pallidus, cannabinoid CB₁ receptors are localized pre-synaptically on GABAergic neurons. We assessed the influence of the endocannabinoids, anandamide, 2-arachidonoyl-glycerol (2-AG) and noladin ether, on the uptake of [³H]-GABA in pallidal slices from rat. Both 2-AG and noladin ether increased [³H]-GABA uptake (by 40.8 ± 8.0% and 38.4 ± 12.5%). The effect of 2-AG was blocked by the cannabinoid CB₁ receptor antagonist AM 251. In contrast, neither anandamide nor the agonist WIN 55,212-2 had an effect on [³H]-GABA uptake. Different roles might be played by different endocannabinoids, both physiologically and in basal ganglia disorders, such as Parkinson's disease.
C02	`01`	`X`		`@0 002B16B`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Cannabinoïde @5 09`
C03	`02`	`X`	`ENG`	`@0 Cannabinoid @5 09`
C03	`02`	`X`	`SPA`	`@0 Canabinoide @5 09`
C03	`03`	`X`	`FRE`	`@0 GABA @2 NK @5 10`
C03	`03`	`X`	`ENG`	`@0 GABA @2 NK @5 10`
C03	`03`	`X`	`SPA`	`@0 GABA @2 NK @5 10`
C03	`04`	`X`	`FRE`	`@0 Captation @5 11`
C03	`04`	`X`	`ENG`	`@0 Uptake @5 11`
C03	`04`	`X`	`SPA`	`@0 Captación @5 11`
C03	`05`	`X`	`FRE`	`@0 Animal @5 12`
C03	`05`	`X`	`ENG`	`@0 Animal @5 12`
C03	`05`	`X`	`SPA`	`@0 Animal @5 12`
C03	`06`	`X`	`FRE`	`@0 Rat @5 13`
C03	`06`	`X`	`ENG`	`@0 Rat @5 13`
C03	`06`	`X`	`SPA`	`@0 Rata @5 13`
C03	`07`	`X`	`FRE`	`@0 Récepteur cannabinoïde CB1 @5 14`
C03	`07`	`X`	`ENG`	`@0 CB1 cannabinoid receptor @5 14`
C03	`07`	`X`	`SPA`	`@0 Receptor canabinoide CB1 @5 14`
C03	`08`	`X`	`FRE`	`@0 Neurone gabaergique @5 15`
C03	`08`	`X`	`ENG`	`@0 Gabaergic neuron @5 15`
C03	`08`	`X`	`SPA`	`@0 Neurona gabaminérgica @5 15`
C03	`09`	`X`	`FRE`	`@0 Glycérol @2 NK @2 FR @5 16`
C03	`09`	`X`	`ENG`	`@0 Glycerol @2 NK @2 FR @5 16`
C03	`09`	`X`	`SPA`	`@0 Glicerol @2 NK @2 FR @5 16`
C03	`10`	`X`	`FRE`	`@0 Noyau gris central @5 17`
C03	`10`	`X`	`ENG`	`@0 Basal ganglion @5 17`
C03	`10`	`X`	`SPA`	`@0 Núcleo basal @5 17`
C07	`01`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`02`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`FRE`	`@0 Neurotransmetteur @5 37`
C07	`04`	`X`	`ENG`	`@0 Neurotransmitter @5 37`
C07	`04`	`X`	`SPA`	`@0 Neurotransmisor @5 37`
C07	`05`	`X`	`FRE`	`@0 Encéphale pathologie @5 38`
C07	`05`	`X`	`ENG`	`@0 Cerebral disorder @5 38`
C07	`05`	`X`	`SPA`	`@0 Encéfalo patología @5 38`
C07	`06`	`X`	`FRE`	`@0 Système nerveux central @5 39`
C07	`06`	`X`	`ENG`	`@0 Central nervous system @5 39`
C07	`06`	`X`	`SPA`	`@0 Sistema nervioso central @5 39`
C07	`07`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`07`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`07`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`08`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`08`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`08`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`09`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 42`
C07	`09`	`X`	`ENG`	`@0 Central nervous system disease @5 42`
C07	`09`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 42`
C07	`10`	`X`	`FRE`	`@0 Système nerveux pathologie @5 43`
C07	`10`	`X`	`ENG`	`@0 Nervous system diseases @5 43`
C07	`10`	`X`	`SPA`	`@0 Sistema nervioso patología @5 43`
N21				`@1 220`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 05-0317987 INIST
ET :	Differential effects of endocannabinoids on [³H]-GABA uptake in the rat globus pallidus
AU :	VENDEROV (Katerina); BROWN (Timothy M.); BROTCHIE (Jonathan M.)
AF :	Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, MC 11-419/Toronto, Ontario, M5T 258/Canada (1 aut., 3 aut.); School of Biological Sciences, University of Manchester/Manchester/Royaume-Uni (2 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Experimental neurology : (Print); ISSN 0014-4886; Coden EXNEAC; Etats-Unis; Da. 2005; Vol. 194; No. 1; Pp. 284-287; Bibl. 25 ref.
LA :	Anglais
EA :	In the globus pallidus, cannabinoid CB₁ receptors are localized pre-synaptically on GABAergic neurons. We assessed the influence of the endocannabinoids, anandamide, 2-arachidonoyl-glycerol (2-AG) and noladin ether, on the uptake of [³H]-GABA in pallidal slices from rat. Both 2-AG and noladin ether increased [³H]-GABA uptake (by 40.8 ± 8.0% and 38.4 ± 12.5%). The effect of 2-AG was blocked by the cannabinoid CB₁ receptor antagonist AM 251. In contrast, neither anandamide nor the agonist WIN 55,212-2 had an effect on [³H]-GABA uptake. Different roles might be played by different endocannabinoids, both physiologically and in basal ganglia disorders, such as Parkinson's disease.
CC :	002B16B; 002B17G
FD :	Parkinson maladie; Cannabinoïde; GABA; Captation; Animal; Rat; Récepteur cannabinoïde CB1; Neurone gabaergique; Glycérol; Noyau gris central
FG :	Rodentia; Mammalia; Vertebrata; Neurotransmetteur; Encéphale pathologie; Système nerveux central; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie
ED :	Parkinson disease; Cannabinoid; GABA; Uptake; Animal; Rat; CB1 cannabinoid receptor; Gabaergic neuron; Glycerol; Basal ganglion
EG :	Rodentia; Mammalia; Vertebrata; Neurotransmitter; Cerebral disorder; Central nervous system; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases
SD :	Parkinson enfermedad; Canabinoide; GABA; Captación; Animal; Rata; Receptor canabinoide CB1; Neurona gabaminérgica; Glicerol; Núcleo basal
LO :	INIST-9181.354000124651760240
ID :	05-0317987

Links to Exploration step

Pascal:05-0317987

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Differential effects of endocannabinoids on [<sup>3</sup>
H]-GABA uptake in the rat globus pallidus</title>
<author><name sortKey="Venderov, Katerina" sort="Venderov, Katerina" uniqKey="Venderov K" first="Katerina" last="Venderov">Katerina Venderov</name>
<affiliation><inist:fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, MC 11-419</s1>
<s2>Toronto, Ontario, M5T 258</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brown, Timothy M" sort="Brown, Timothy M" uniqKey="Brown T" first="Timothy M." last="Brown">Timothy M. Brown</name>
<affiliation><inist:fA14 i1="02"><s1>School of Biological Sciences, University of Manchester</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation><inist:fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, MC 11-419</s1>
<s2>Toronto, Ontario, M5T 258</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0317987</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0317987 INIST</idno>
<idno type="RBID">Pascal:05-0317987</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000901</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Differential effects of endocannabinoids on [<sup>3</sup>
H]-GABA uptake in the rat globus pallidus</title>
<author><name sortKey="Venderov, Katerina" sort="Venderov, Katerina" uniqKey="Venderov K" first="Katerina" last="Venderov">Katerina Venderov</name>
<affiliation><inist:fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, MC 11-419</s1>
<s2>Toronto, Ontario, M5T 258</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brown, Timothy M" sort="Brown, Timothy M" uniqKey="Brown T" first="Timothy M." last="Brown">Timothy M. Brown</name>
<affiliation><inist:fA14 i1="02"><s1>School of Biological Sciences, University of Manchester</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation><inist:fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, MC 11-419</s1>
<s2>Toronto, Ontario, M5T 258</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Experimental neurology : (Print)</title>
<title level="j" type="abbreviated">Exp. neurol. : (Print)</title>
<idno type="ISSN">0014-4886</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Experimental neurology : (Print)</title>
<title level="j" type="abbreviated">Exp. neurol. : (Print)</title>
<idno type="ISSN">0014-4886</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Basal ganglion</term>
<term>CB1 cannabinoid receptor</term>
<term>Cannabinoid</term>
<term>GABA</term>
<term>Gabaergic neuron</term>
<term>Glycerol</term>
<term>Parkinson disease</term>
<term>Rat</term>
<term>Uptake</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Cannabinoïde</term>
<term>GABA</term>
<term>Captation</term>
<term>Animal</term>
<term>Rat</term>
<term>Récepteur cannabinoïde CB1</term>
<term>Neurone gabaergique</term>
<term>Glycérol</term>
<term>Noyau gris central</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the globus pallidus, cannabinoid CB<sub>1</sub>
 receptors are localized pre-synaptically on GABAergic neurons. We assessed the influence of the endocannabinoids, anandamide, 2-arachidonoyl-glycerol (2-AG) and noladin ether, on the uptake of [<sup>3</sup>
H]-GABA in pallidal slices from rat. Both 2-AG and noladin ether increased [<sup>3</sup>
H]-GABA uptake (by 40.8 ± 8.0% and 38.4 ± 12.5%). The effect of 2-AG was blocked by the cannabinoid CB<sub>1</sub>
 receptor antagonist AM 251. In contrast, neither anandamide nor the agonist WIN 55,212-2 had an effect on [<sup>3</sup>
H]-GABA uptake. Different roles might be played by different endocannabinoids, both physiologically and in basal ganglia disorders, such as Parkinson's disease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0014-4886</s0>
</fA01>
<fA02 i1="01"><s0>EXNEAC</s0>
</fA02>
<fA03 i2="1"><s0>Exp. neurol. : (Print)</s0>
</fA03>
<fA05><s2>194</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Differential effects of endocannabinoids on [<sup>3</sup>
H]-GABA uptake in the rat globus pallidus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VENDEROV (Katerina)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BROWN (Timothy M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BROTCHIE (Jonathan M.)</s1>
</fA11>
<fA14 i1="01"><s1>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, MC 11-419</s1>
<s2>Toronto, Ontario, M5T 258</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>School of Biological Sciences, University of Manchester</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>284-287</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>9181</s2>
<s5>354000124651760240</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0317987</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Experimental neurology : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In the globus pallidus, cannabinoid CB<sub>1</sub>
 receptors are localized pre-synaptically on GABAergic neurons. We assessed the influence of the endocannabinoids, anandamide, 2-arachidonoyl-glycerol (2-AG) and noladin ether, on the uptake of [<sup>3</sup>
H]-GABA in pallidal slices from rat. Both 2-AG and noladin ether increased [<sup>3</sup>
H]-GABA uptake (by 40.8 ± 8.0% and 38.4 ± 12.5%). The effect of 2-AG was blocked by the cannabinoid CB<sub>1</sub>
 receptor antagonist AM 251. In contrast, neither anandamide nor the agonist WIN 55,212-2 had an effect on [<sup>3</sup>
H]-GABA uptake. Different roles might be played by different endocannabinoids, both physiologically and in basal ganglia disorders, such as Parkinson's disease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B16B</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Cannabinoïde</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cannabinoid</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Canabinoide</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>GABA</s0>
<s2>NK</s2>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>GABA</s0>
<s2>NK</s2>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>GABA</s0>
<s2>NK</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Captation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Uptake</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Captación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Animal</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Animal</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Animal</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Rat</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Rat</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Rata</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Récepteur cannabinoïde CB1</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>CB1 cannabinoid receptor</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Receptor canabinoide CB1</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Neurone gabaergique</s0>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Gabaergic neuron</s0>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Neurona gabaminérgica</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Glycérol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Glycerol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Glicerol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Noyau gris central</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Basal ganglion</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Núcleo basal</s0>
<s5>17</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>43</s5>
</fC07>
<fN21><s1>220</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 05-0317987 INIST</NO>
<ET>Differential effects of endocannabinoids on [<sup>3</sup>
H]-GABA uptake in the rat globus pallidus</ET>
<AU>VENDEROV (Katerina); BROWN (Timothy M.); BROTCHIE (Jonathan M.)</AU>
<AF>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, MC 11-419/Toronto, Ontario, M5T 258/Canada (1 aut., 3 aut.); School of Biological Sciences, University of Manchester/Manchester/Royaume-Uni (2 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Experimental neurology : (Print); ISSN 0014-4886; Coden EXNEAC; Etats-Unis; Da. 2005; Vol. 194; No. 1; Pp. 284-287; Bibl. 25 ref.</SO>
<LA>Anglais</LA>
<EA>In the globus pallidus, cannabinoid CB<sub>1</sub>
 receptors are localized pre-synaptically on GABAergic neurons. We assessed the influence of the endocannabinoids, anandamide, 2-arachidonoyl-glycerol (2-AG) and noladin ether, on the uptake of [<sup>3</sup>
H]-GABA in pallidal slices from rat. Both 2-AG and noladin ether increased [<sup>3</sup>
H]-GABA uptake (by 40.8 ± 8.0% and 38.4 ± 12.5%). The effect of 2-AG was blocked by the cannabinoid CB<sub>1</sub>
 receptor antagonist AM 251. In contrast, neither anandamide nor the agonist WIN 55,212-2 had an effect on [<sup>3</sup>
H]-GABA uptake. Different roles might be played by different endocannabinoids, both physiologically and in basal ganglia disorders, such as Parkinson's disease.</EA>
<CC>002B16B; 002B17G</CC>
<FD>Parkinson maladie; Cannabinoïde; GABA; Captation; Animal; Rat; Récepteur cannabinoïde CB1; Neurone gabaergique; Glycérol; Noyau gris central</FD>
<FG>Rodentia; Mammalia; Vertebrata; Neurotransmetteur; Encéphale pathologie; Système nerveux central; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie</FG>
<ED>Parkinson disease; Cannabinoid; GABA; Uptake; Animal; Rat; CB1 cannabinoid receptor; Gabaergic neuron; Glycerol; Basal ganglion</ED>
<EG>Rodentia; Mammalia; Vertebrata; Neurotransmitter; Cerebral disorder; Central nervous system; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases</EG>
<SD>Parkinson enfermedad; Canabinoide; GABA; Captación; Animal; Rata; Receptor canabinoide CB1; Neurona gabaminérgica; Glicerol; Núcleo basal</SD>
<LO>INIST-9181.354000124651760240</LO>
<ID>05-0317987</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000901 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000901 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0317987
   |texte=   Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus

Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri